Usp44 (NM_183199) Mouse Tagged ORF Clone Lentiviral Particle
CAT#: MR222450L4V
- LentiORF®
Lenti ORF particles, Usp44 (GFP-tagged) - Mouse ubiquitin specific peptidase 44 (Usp44), 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 10,735.00
货期*
详询
规格
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | Usp44 (NM_183199) Mouse Tagged ORF Clone Lentiviral Particle |
Synonyms | E430004F17Rik |
Vector | pLenti-C-mGFP-P2A-Puro |
ACCN | NM_183199 |
ORF Size | 1515 bp |
Sequence Data |
The ORF insert of this clone is exactly the same as(MR222450).
|
OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
Reference Data | |
RefSeq | NM_183199.3, NP_899022.2 |
RefSeq Size | 2946 bp |
RefSeq ORF | 1518 bp |
Locus ID | 327799 |
Gene Summary | Deubiquitinase that plays a key regulatory role in the spindle assembly checkpoint or mitotic checkpoint by preventing premature anaphase onset. Acts by specifically mediating deubiquitination of CDC20, a negative regulator of the anaphase promoting complex/cyclosome (APC/C). Deubiquitination of CDC20 leads to stabilize the MAD2L1-CDC20-APC/C ternary complex (also named mitotic checkpoint complex), thereby preventing premature activation of the APC/C. Promotes association of MAD2L1 with CDC20 and reinforces the spindle assembly checkpoint. Acts as a negative regulator of histone H2B (H2BK120ub1) ubiquitination.[UniProtKB/Swiss-Prot Function] |
Documents
Product Manuals |
FAQs |
SDS |
Resources
You may also need
Customer
Reviews
Loading...